OptiBiotix Health PLC License agreement with Tata Chemicals (8588Q)

TIDMOPTI

RNS Number : 8588Q

OptiBiotix Health PLC

23 October 2023

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

License agreement with Tata Chemicals

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, announces that it has reached an agreement with Tata Chemicals Limited ("Tata Chemicals") to incorporate its proprietary Fossence (R) into SlimBiome (R) and LeanBiome (R) for the Indian market.

The agreement incorporates Tata's Fossence (R) , a proprietary short chain fructo-oligosaccharide ("FOS") into OptiBiotix's SlimBiome (R) and LeanBiome (R) products for the Indian market. Fossence (R) will be a direct replacement for the FOS used in SlimBiome (R) in other markets and brings scientific substantiation of health benefits shown by FOS in the Indian market (see Explore - Brochures, Whitepapers, Concept Notes & More | Tata NQ ). Tata Chemicals have approved the use of the Fossence (R) logo on products containing SlimBiome(R) in India bringing a branded ingredient from a well-known and trusted source to the attention of Indian consumers.

Tata Chemicals is a global science company active in industrial chemicals, food and nutrition (Tata NQ), and agriculture listed on the Indian stock Exchange. It is part of the Tata Group which employs over one million people with annual revenues in 2022 of $300billion.

S tep hen O'Ha r a, CEO of O pti B i oti x, c o mmented: "We are pleased to report this agreement with Tata Chemicals which creates the opportunity to bring products containing Tatas proprietary Fossence (R) in SlimBiome (R) and LeanBiome (R) to the Indian market. Tata Chemicals is one of India's leading suppliers of food ingredients with many well-known and respected brands. Fossence's (R) established health benefits with Indian consumers and its trusted brand combined with SlimBiome's (R) strong science, clinical studies, and excellent customer reviews will help reduce hunger and food cravings to support the weight management efforts of India's 135 million obese men and women ."

For further information, please contact:

 
 OptiBiotix Health plc                                   www.optibiotix.com 
 Neil Davidson, Chairman                         Contact via Walbrook below 
 Stephen O'Hara, Chief Executive 
 
 Cairn Financial Advisers LLP (NOMAD)                    Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 Peterhouse Capital Limited (Broker)                     Tel: [phone] 
 Duncan Vasey / Lucy Williams 
 
 Walbrook PR Ltd                                         Mob: [phone] 
 Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFLEIRLIFIV

(END) Dow Jones Newswires

October 23, 2023 02:00 ET (06:00 GMT)